Short Interest in Klotho Neurosciences, Inc. (NASDAQ:KLTO) Rises By 94.2%

Klotho Neurosciences, Inc. (NASDAQ:KLTO) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 482,725 shares, a growth of 94.2% from the December 15th total of 248,611 shares. Approximately 0.9% of the company’s shares are sold short. Based on an average trading volume of 835,806 shares, the short-interest ratio is currently 0.6 days. Based on an average trading volume of 835,806 shares, the short-interest ratio is currently 0.6 days. Approximately 0.9% of the company’s shares are sold short.

Institutional Investors Weigh In On Klotho Neurosciences

A hedge fund recently bought a new stake in Klotho Neurosciences stock. Jane Street Group LLC purchased a new position in shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned approximately 0.05% of Klotho Neurosciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 20.07% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Klotho Neurosciences in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Klotho Neurosciences Price Performance

NASDAQ KLTO traded up $0.03 during mid-day trading on Thursday, hitting $0.33. The company’s stock had a trading volume of 1,228,116 shares, compared to its average volume of 632,210. The firm has a market capitalization of $23.92 million, a P/E ratio of -1.03 and a beta of 10.27. Klotho Neurosciences has a 52-week low of $0.11 and a 52-week high of $3.91. The stock’s fifty day simple moving average is $0.41 and its two-hundred day simple moving average is $0.65.

Klotho Neurosciences (NASDAQ:KLTO) last issued its earnings results on Thursday, November 13th. The company reported ($0.05) EPS for the quarter.

About Klotho Neurosciences

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.